DDInter528 DDInter1676
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Disopyramide
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Dextropropoxyphene {u} (Compound) resembles {v} (Compound) Levacetylmethadol
Dextropropoxyphene {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dextropropoxyphene {u} (Compound) upregulates {v} (Gene) UBQLN2
Dextropropoxyphene {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dextropropoxyphene {u} (Compound) downregulates {v} (Gene) RUVBL1
Dextropropoxyphene {u} (Compound) causes {v} (Side Effect) Asthenia
Dextropropoxyphene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Dextropropoxyphene (Compound) resembles Disopyramide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Dextropropoxyphene (Compound) binds CYP3A7-CYP3A51P (Gene)
Dextropropoxyphene (Compound) upregulates UBQLN2 (Gene)
Dextropropoxyphene (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dextropropoxyphene (Compound) downregulates RUVBL1 (Gene)
Dextropropoxyphene (Compound) causes Asthenia (Side Effect)
Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole